Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
274,772,727
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
14,700,530
-
Shares change
-
-2,290,617
-
Total reported value, excl. options
-
$54,695,000
-
Value change
-
-$11,594,670
-
Put/Call ratio
-
0%
-
Number of buys
-
28
-
Number of sells
-
-47
-
Price
-
$3.72
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q2 2022
82 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value as of Q2 2022.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) has 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14,700,530 shares
of 274,772,727 outstanding shares and own 5.4% of the company stock.
Largest 10 shareholders include FMR LLC (3,295,681 shares), Nantahala Capital Management, LLC (1,643,438 shares), VANGUARD GROUP INC (1,070,802 shares), BlackRock Inc. (1,046,490 shares), Artal Group S.A. (1,040,882 shares), FRANKLIN RESOURCES INC (811,069 shares), Sands Capital Ventures, LLC (724,873 shares), Alphabet Inc. (640,882 shares), RENAISSANCE TECHNOLOGIES LLC (523,600 shares), and TYBOURNE CAPITAL MANAGEMENT (HK) LTD (500,000 shares).
This table shows the top 55 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.